What is William Blair’s Forecast for FibroGen Q1 Earnings?

FibroGen, Inc. (NASDAQ:FGEN) – William Blair issued their Q1 2025 earnings estimates for shares of FibroGen in a note issued to investors on Tuesday, March 18th. William Blair analyst A. Hsieh anticipates that the biopharmaceutical company will post earnings per share of $0.02 for the quarter. The consensus estimate for FibroGen’s current full-year earnings is ($0.80) per share. William Blair also issued estimates for FibroGen’s Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.22) EPS, Q4 2025 earnings at ($0.22) EPS, FY2025 earnings at ($0.88) EPS, FY2026 earnings at ($0.86) EPS and FY2027 earnings at ($0.72) EPS.

Other research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of FibroGen in a research report on Tuesday. StockNews.com started coverage on FibroGen in a report on Friday, March 14th. They issued a “hold” rating for the company.

FibroGen Stock Up 2.8 %

Shares of FGEN opened at $0.36 on Thursday. The company has a 50 day moving average of $0.50 and a 200-day moving average of $0.43. The stock has a market capitalization of $36.05 million, a P/E ratio of -0.29 and a beta of 0.82. FibroGen has a twelve month low of $0.18 and a twelve month high of $2.80.

FibroGen (NASDAQ:FGEN) last released its earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.08). The firm had revenue of $3.14 million for the quarter, compared to the consensus estimate of $24.91 million.

Hedge Funds Weigh In On FibroGen

Hedge funds and other institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in FibroGen by 430.7% during the third quarter. JPMorgan Chase & Co. now owns 1,673,555 shares of the biopharmaceutical company’s stock worth $668,000 after acquiring an additional 1,358,194 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of FibroGen by 80.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,358,712 shares of the biopharmaceutical company’s stock valued at $719,000 after purchasing an additional 605,572 shares during the period. Geode Capital Management LLC lifted its stake in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after purchasing an additional 32,884 shares during the last quarter. Two Sigma Advisers LP grew its holdings in FibroGen by 18.3% during the fourth quarter. Two Sigma Advisers LP now owns 878,400 shares of the biopharmaceutical company’s stock worth $465,000 after purchasing an additional 135,600 shares during the period. Finally, Two Sigma Investments LP increased its position in FibroGen by 19.6% during the fourth quarter. Two Sigma Investments LP now owns 604,421 shares of the biopharmaceutical company’s stock worth $320,000 after buying an additional 98,888 shares during the last quarter. 72.71% of the stock is owned by institutional investors.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.